Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Thermo Fisher Scientific's accounts receivables for the quarter that ended in Jun. 2026 was R$48,428 Mil.
Accounts receivable can be measured by Days Sales Outstanding.
Thermo Fisher Scientific's Days Sales Outstanding for the quarter that ended in Jun. 2026 was 71.90.
In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Thermo Fisher Scientific's Net-Net Working Capital per share for the quarter that ended in Jun. 2026 was R$-13.36.
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.
Thermo Fisher Scientific's Days Sales Outstanding for the quarter that ended in Jun. 2026 is calculated as:
2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Thermo Fisher Scientific's accounts receivable are only considered to be worth 75% of book value:
Thermo Fisher Scientific's Net-Net Working Capital Per Share for the quarter that ended in Jun. 2026 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.
If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.
Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.
Thermo Fisher Scientific Accounts Receivable Related Terms
Thermo Fisher Scientific Accounts Receivable Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Accounts Receivable of R$48,428 Mil mean?
Thermo Fisher Scientific (BSP:TMOS34) has a Accounts Receivable of R$48,428 Mil as of Jun. 2026. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on Thermo Fisher Scientific and its competitors.
Is Thermo Fisher Scientific's Accounts Receivable too high?
Thermo Fisher Scientific's current Accounts Receivable is R$48,428 Mil. Overall, Thermo Fisher Scientific has a GF Score™ of 71/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Thermo Fisher Scientific's Accounts Receivable compare to DHR and IDXX?
Thermo Fisher Scientific's Accounts Receivable of R$48,428 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Receivable for a Medical Diagnostics & Research company?
A good Accounts Receivable depends on the Medical Diagnostics & Research industry context. However, Accounts Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Receivable mean?
A high Accounts Receivable can signal that a stock is expensive relative to its fundamentals. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on Thermo Fisher Scientific and its competitors. Thermo Fisher Scientific's current Accounts Receivable is R$48,428 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Thermo Fisher Scientific stock overvalued right now?
Based on GuruFocus' analysis, Thermo Fisher Scientific (BSP:TMOS34) is currently considered Fairly Valued. The stock's GF Value™ is R$62.04, compared to a current price of R$60.43 — trading 2.6% below its estimated fair value. The current Accounts Receivable is R$48,428 Mil. Thermo Fisher Scientific's overall GF Score™ is 71/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Receivable calculated?
Accounts Receivable is calculated from a company's financial statements. For Thermo Fisher Scientific (BSP:TMOS34), the current Accounts Receivable is R$48,428 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Thermo Fisher Scientific (BSP:TMOS34) Overvalued in 2026?
Based on GuruFocus' analysis, Thermo Fisher Scientific stock appears to be undervalued.
The current stock price of R$60.43 is trading 2.6% below its estimated GF Value™ of R$62.04.
GuruFocus considers Thermo Fisher Scientific to be Fairly Valued.
Key valuation signals for BSP:TMOS34:
Accounts Receivable: R$48,428 Mil
GF Value™: R$62.04 vs. price of R$60.43 (2.6% below fair value)
No single metric tells the full story. See the BSP:TMOS34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2025 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).
71GF Score
Get the complete analysis for BSP:TMOS34
Accounts Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:TMOS34 has been successfully added to your 
